World’s largest study of cardiovascular disease in type 2 diabetes shows need for improved knowledge and disease management
Bagsværd, Denmark, 24 September 2020 – Novo Nordisk today announced the results of the CAPTURE study, a global non-interventional study to uncover the prevalence of cardiovascular disease and risk and its management in people living with type 2 diabetes. The study, the first of its kind and involving nearly 10,000 participants from 13 countries across five continents, showed that 1 in 3 people with type 2 diabetes have established cardiovascular disease, and 9 in 10 of these had atherosclerotic cardiovascular disease. Atherosclerotic cardiovascular disease is caused by the build-up of fats, cholesterol and other substances in and on the artery walls, which narrows the vessels and results in reduced blood flow, potentially leading to events like heart attack and stroke. CAPTURE also highlighted that only 2 in 10 people with type 2 diabetes and atherosclerotic cardiovascular disease are receiving a glucose-lowering treatment with proven cardiovascular benefits.
“The findings of the CAPTURE study are significant for anyone involved in the care of people with type 2 diabetes. The data highlight that while the prevalence of atherosclerotic cardiovascular disease within the type 2 diabetes population is high, the vast majority are not being managed with treatments that are proven to reduce the risk of potentially life-altering cardiovascular events,” said study investigator Dr Ofri Mosenzon, who consults for Novo Nordisk and the Diabetes Unit at the Hadassah Medical Center in Israel. “It is critical that we prioritise cardiovascular disease as a key factor in the management of type 2 diabetes. People with type 2 diabetes need to be more aware of their risk factors and physicians need to be actively screening for them. Today, we can address this risk through treatments with proven cardiovascular benefits, as recommended by various treatment guidelines.”
For the first time, information on cardiovascular disease in type 2 diabetes has been gathered from both primary and secondary care settings, also reflecting that a significant proportion of people with type 2 diabetes are being treated by primary care physicians in conjunction with diabetes specialists.
“Cardiovascular disease is the leading cause of disability and death among people with type 2 diabetes. Until recently, the importance of this link between type 2 diabetes and cardiovascular disease was not fully recognised on a global scale,” said Stephen Gough, chief medical officer at Novo Nordisk. “Through our ongoing investment, including the CAPTURE study, Novo Nordisk hopes that with increased understanding of the disease and its management, healthcare professionals will have greater knowledge of the most appropriate way to manage this disease and improve patient outcomes.”
For more information on the CAPTURE study, please visit:
CAPTURE is the first global non-interventional study to capture the prevalence of cardiovascular disease and risk and its management in people living with type 2 diabetes. The objectives were to establish the proportion of people with type 2 diabetes at high risk of cardiovascular disease and atherosclerotic cardiovascular disease, and to document the use of cardiovascular risk-reducing medicines in people with type 2 diabetes and established cardiovascular disease. Atherosclerotic cardiovascular disease was defined as cerebrovascular disease (including carotid artery disease), coronary heart disease and/or peripheral artery disease. The CAPTURE study, sponsored by Novo Nordisk, was conducted in Argentina, Australia, Brazil, Czech Republic, China, France, Hungary, Israel, Italy, Japan, Mexico, Kingdom of Saudi Arabia and Turkey, involving nearly 10,000 people with type 2 diabetes. Participants had to be at least 18 years of age and diagnosed with type 2 diabetes for at least 180 days.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 43,500 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.
|Mette Kruse Danielsen||+45 3079 email@example.com|
|Daniel Muusmann Bohsen||+45 3075 firstname.lastname@example.org|
|Valdemar Borum Svarrer||+45 3079 email@example.com|
|Ann Søndermølle Rendbæk||+45 3075 firstname.lastname@example.org|
|Mark Joseph Root||+45 3079 email@example.com|
1. Mosenzon O, Alguwaihes A, Arenas Leon J.L., et al. CAPTURE: a cross-sectional study of the contemporary (2019) prevalence of cardiovascular disease in adults with type 2 diabetes across 13 countries. Abstract 158. Presented at the 56th Annual Meeting of the European Association of the Study of Diabetes, Macrovascular complications and beyond, 10:15 CEST on 24 September 2020.
2. National Institute of Health (NIH). Atherosclerosis. Available at: https://www.nhlbi.nih.gov/health-topics/atherosclerosis Last accessed: September 2020.
3. Vencio S, Alguwaihes A, Arenas Leon J.L., et al. Contemporary use of diabetes medications with a cardiovascular indication in adults with type 2 diabetes: a secondary analysis of the multinational CAPTURE study. Abstract 945. Presented at the 56th Annual Meeting of the European Association of the Study of Diabetes, Cardiovascular complications in humans through and through, 13:15 CEST on 22 September 2020.
4. ClinicalTrials.gov. An International Survey of the Occurrence of Cardiovascular Disease Among Patients With Type 2 Diabetes (CAPTURE-IO). Available at: https://clinicaltrials.gov/ct2/show/NCT03811288. Last accessed: September 2020.
Upcoming Life Sciences Events
- October 2020
- European Standard Time: BIO-Europe® 2020
- AusBiotech + Invest 2020
- November 2020
- Precision in Clinical Trials Summit San Francisco